Paul Hopper on C0 nstant In vest0r, page-2

I like this.

“Phase two data is the data is the data where you usually get brought out by a big pharma company and the data has to be good.”

“What does the data look like?
We haven’t got any data out of the trial in Asia yet because it’s too early, you have to be careful you report when you have a sufficient body.  If you get one patient with results sure it will be exciting but that can easily be followed by a patient that has no decent responses.  The phase two which is in Ohio State University and in the Mayo Clinic has got quite encouraging data and of course the third one we won’t know until we start next year.”